Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial
S. Bueno*, Katia Abarca, Pablo A. González, Nicolás M.S. Gálvez, Jorge A. Soto, Luisa F. Duarte, Bárbara M. Schultz, Gaspar A. Pacheco, Liliana A. González, Yaneisi Vázquez, Mariana Ríos, Felipe Melo-González, Daniela Rivera-Pérez, Carolina Iturriaga, Marcela Urzúa, Angélica Domínguez, Catalina A. Andrade, Roslye V. Berríos-Rojas, Gisela Canedo-Marroquín, Camila CoviánDaniela Moreno-Tapia, Farides Saavedra, Omar P. Vallejos, Paulina Donato, Pilar Espinoza, Daniela Fuentes, Marcela González, Paula Guzmán, Paula Muñoz-Venturelli, Carlos M. Perez, Marcela Potin, Álvaro Rojas, Rodrigo Fasce, Jorge Fernández, Judith Mora, Eugenio Ramírez, Aracelly Gaete-Argel, Aarón Oyarzún-Arrau, Fernando Valiente-Echeverría, Ricardo Soto-Rifo, Daniela Weiskopf, Alessandro Sette, Gang Zeng, Weining Meng, José V. González-Aramundiz, Alexis M. Kalergis*
*Corresponding author for this work
Research output: Contribution to journal › Article
Fingerprint
Dive into the research topics of 'Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial'. Together they form a unique fingerprint.